| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Petrolatum (yellow) does not have a defined pharmacological target as it is a pharmaceutical excipient and topical ointment base. The compound is used as an ointment base, lubricant, adhesive, thickener, and pharmaceutical excipient. It is used as a topical ointment, as a laxative base, and as a carrier for rust preventatives. In pharmaceuticals, it serves as an excipient or inactive ingredient in drug formulations.
|
|---|---|
| ln Vitro |
No specific in vitro pharmacological activity data are available for Petrolatum (yellow) as it is a pharmaceutical excipient and topical base. In research settings, the compound is evaluated for its physical properties, compatibility with active pharmaceutical ingredients, and formulation performance rather than direct biological activity. It is used as an ointment base, lubricant, and thickening agent in various formulations.
|
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for Petrolatum (yellow) as it is a pharmaceutical excipient. The compound is used in topical formulations and as a base for ointments and creams. It is generally considered pharmacologically inert and is not absorbed to a significant extent after topical or oral administration. Its primary function is as a formulation component.
|
| Enzyme Assay |
For non-cellular assays, Petrolatum (yellow) is characterized by standard analytical techniques including FTIR, melting point determination, and physical property testing to confirm identity and quality. The compound can be evaluated for its physical properties including melting point (38-54°C), boiling point (302°C), and consistency. Typical protocols involve testing the compound's suitability as an ointment base or formulation excipient.
|
| Cell Assay |
For in vitro cell-based studies, Petrolatum (yellow) is not typically used as a direct test compound. The compound is used as an excipient in pharmaceutical formulations that are subsequently tested in cell-based assays. If handled in a biological laboratory context, standard safety precautions should be taken. The compound should be stored in a cool, dry place protected from light and moisture.
|
| Animal Protocol |
For in vivo animal studies, Petrolatum (yellow) is used as an excipient in pharmaceutical formulations administered to animals. The compound is generally considered safe for use in topical and oral formulations. Dosing and administration follow the specific formulation protocol. Standard animal welfare guidelines should be followed for all in vivo studies.
|
| ADME/Pharmacokinetics |
Petrolatum (yellow) has a CAS number of 8009-03-8. It has a boiling point of 302°C and melting point of 38-54°C. Storage: keep in a cool, dry place protected from light and moisture. The compound is a semi-solid at room temperature that becomes liquid above 54°C. It is a complex combination of hydrocarbons obtained as a semi-solid from dewaxing.
|
| Toxicity/Toxicokinetics |
Petrolatum (yellow) is generally regarded as safe for use as a pharmaceutical excipient and topical ointment base. The compound meets USP and FDA requirements. Standard laboratory safety practices should be followed when handling this compound. Appropriate personal protective equipment including gloves and safety glasses should be worn.
|
| References |
[1]. Elder DP, et al. Pharmaceutical excipients - quality, regulatory and biopharmaceutical considerations. Eur J Pharm Sci. 2016 May 25;87:88-99.
|
| Additional Infomation |
Petrolatum (yellow) (CAS 8009-03-8) is also known as yellow vaseline, petroleum jelly, and mineral jelly. It has an EINECS number of 232-373-2. Applications include use as an ointment base, lubricant, adhesive, thickener, and pharmaceutical excipient. It is used in cosmetics, pharmaceuticals, food, and general industrial applications. No therapeutic claims exist for the compound itself.
|
| Molecular Formula |
C6H9NO2
|
|---|---|
| Molecular Weight |
127.141161680222
|
| CAS # |
8009-03-8
|
| Appearance |
White to light yellow <38°C powder,>54°C liquid
|
| Density |
0.84
|
| Boiling Point |
322 °C
|
| Melting Point |
70-80 °C ((ASTM D 127))
|
| Flash Point |
198 °C
|
| Index of Refraction |
n20/D 1.45
|
| SMILES |
OC(C1(CC1C=C)N)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.8653 mL | 39.3267 mL | 78.6535 mL | |
| 5 mM | 1.5731 mL | 7.8653 mL | 15.7307 mL | |
| 10 mM | 0.7865 mL | 3.9327 mL | 7.8653 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
